Cann Group（CAN）株式概要キャン・グループ・リミテッドはその子会社とともに、オーストラリアとヨーロッパで薬用大麻の育種、栽培、製造、販売を行っている。 詳細CAN ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性1/6配当金0/6報酬株価収益率（ 0.4 x） Australian市場（ 17.2 x）を下回っています。今年は黒字化を達成 リスク分析過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( A$7M )Australian市場と比較して、過去 3 か月間の株価の変動が非常に大きい負債は営業キャッシュフローで十分にカバーされていない +1 さらなるリスクすべてのリスクチェックを見るCAN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueAU$Current PriceAU$0.004207.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-48m26m2016201920222025202620282031Revenue AU$19.7mEarnings AU$25.7mAdvancedSet Fair ValueView all narrativesCann Group Limited 競合他社Vitura HealthSymbol: ASX:VITMarket cap: AU$22.5mVita Life SciencesSymbol: ASX:VLSMarket cap: AU$130.4mNeuren PharmaceuticalsSymbol: ASX:NEUMarket cap: AU$1.8bSunil HealthcareSymbol: BSE:537253Market cap: ₹651.2m価格と性能株価の高値、安値、推移の概要Cann Group過去の株価現在の株価AU$0.00452週高値AU$0.02352週安値AU$0.004ベータ0.151ヶ月の変化-27.27%3ヶ月変化-50.00%1年変化-71.43%3年間の変化-97.58%5年間の変化-99.06%IPOからの変化-99.38%最新ニュースNew Risk • Mar 04New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (32% accrual ratio). Shareholders have been substantially diluted in the past year (191% increase in shares outstanding). Market cap is less than US$10m (AU$11.1m market cap, or US$7.86m).お知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listingお知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australiaお知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069Reported Earnings • Sep 30Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 24% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.8m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$2.8m). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (AU$11.9m market cap, or US$7.87m).最新情報をもっと見るRecent updatesNew Risk • Mar 04New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (32% accrual ratio). Shareholders have been substantially diluted in the past year (191% increase in shares outstanding). Market cap is less than US$10m (AU$11.1m market cap, or US$7.86m).お知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listingお知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australiaお知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069Reported Earnings • Sep 30Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 24% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.8m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$2.8m). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (AU$11.9m market cap, or US$7.87m).New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$9.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.8m free cash flow). Negative equity (-AU$2.8m). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Market cap is less than US$10m (AU$9.12m market cap, or US$5.97m). Minor Risk Share price has been volatile over the past 3 months (17% average weekly change).Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).分析記事 • Jul 20Cann Group Limited's (ASX:CAN) Share Price Boosted 36% But Its Business Prospects Need A Lift TooCann Group Limited ( ASX:CAN ) shareholders are no doubt pleased to see that the share price has bounced 36% in the...お知らせ • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.分析記事 • Jun 02Investors Aren't Buying Cann Group Limited's (ASX:CAN) RevenuesCann Group Limited's ( ASX:CAN ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy right now...New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (AU$9.65m market cap, or US$6.17m). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).New Risk • Apr 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (AU$10.2m market cap, or US$6.58m).お知らせ • Apr 14Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Apr 08Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct ListingNew Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (AU$13.4m market cap, or US$8.56m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Shareholders have been diluted in the past year (22% increase in shares outstanding).お知らせ • Mar 12Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: AUD 0.015 Transaction Features: Subsequent Direct ListingNew Risk • Feb 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$16.1m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (AU$16.1m market cap, or US$9.89m). Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).分析記事 • Jan 31The Market Doesn't Like What It Sees From Cann Group Limited's (ASX:CAN) Revenues YetCann Group Limited's ( ASX:CAN ) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now...お知らせ • Dec 06Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,724,489 Price\Range: AUD 0.04 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,675,343 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Oct 09Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 156,312,161 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering分析記事 • Sep 24Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%Despite an already strong run, Cann Group Limited ( ASX:CAN ) shares have been powering on, with a gain of 36% in the...お知らせ • Sep 03Cann Group Limited, Annual General Meeting, Oct 28, 2024Cann Group Limited, Annual General Meeting, Oct 28, 2024.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.お知らせ • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024お知らせ • Jul 15+ 1 more updateCann Group Limited Appoints Jenni Pilcher as Managing DirectorCann Group Limited announced that it has executed an employment agreement to formally appoint Ms. Jenni Pilcher to the role of CEO & Managing Director. Jenni joined Cann as a Non-executive Director on 15 September 2020. In February 2024, Jenni stepped into an Executive Director role to provide financial oversight of the Company, transitioning to Interim CEO following the notice of resignation of the CEO on 21 March 2024. Chairman, Julian Chick, commented: "Since stepping in as Executive Director in February, Jenni has implemented a restructure and cost savings plan which will generate at least $2.15 million savings per annum. Following on from this, Jenni successfully managed the re-release of the Company's half-year financial report in May accompanied by an audit review report free from disclaimers, secured a further $5 million debt to fund the business, and achieved the ASX's reinstatement of CAN securities to trading in June. Jenni has over 15 years of senior finance executive experience in the medical, biotechnology and technology sectors, within small-mid cap ASX-listed companies. In addition to financial management, investor relations and corporate governance experience, Jenni has successfully completed multiple capital raisings and M&A transactions, including company acquisitions, asset sales, and a takeover defense. Most recently, Jenni was Chief Financial Officer & Company Secretary of technology communications company Whispir Ltd, and prior to that was CFO & Company Secretary of digital imaging company, Mach7 Technologies. She has also previously held CFO roles with Australia biotechnology companies Alchemia Limited and Mesoblast Limited. Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand. Ms. Pilcher will be appointed for a fixed term ending on 1 July 2025, subject to termination by either party. The fixed term can be extended at any time by mutual agreement, in writing, between Ms. Pilcher and the Company.Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Jun 04Cann Group Limited's (ASX:CAN) Low P/S No Reason For ExcitementWith a price-to-sales (or "P/S") ratio of 1x Cann Group Limited ( ASX:CAN ) may be sending very bullish signals at the...New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (AU$27.1m market cap, or US$17.6m).お知らせ • Jan 08+ 1 more updateCann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory AffairsCann Group Limited announced that Tony Di Pietro will act as joint Company Secretary with Steven Notaro, Head of Legal and Regulatory Affairs at Cann Group. . Having spent the past two decades at ASX-listed companies, Mr. Di Pietro boasts extensive experience as CFO/Company Secretary in the med-tech industry, with his last three roles at Sienna Cancer Diagnostics Limited (November 2014 - July 2020), INOVIQ Limited (July 2020 - November 2022) and Genetic Technologies Limited (November 2022 - present). In his most recent role at Genetic Technologies, Mr. Di Pietro managed a capital raising of $5 million from US-based investors and was responsible for both US and Australian due diligence activities and compliance with both ASX/Corporations Act & NASDAQ/SEC regulations. Mr. Di Pietro's qualifications include: A Bachelor of Commerce (BCom),Accounting and Finance, from Swinburne University of Technology;Chartered Accountants (CA) accreditation (1989-2000); Graduate Diploma of Applied Corporate Governancefrom the Governance Institute of Australia(2012-2014); and Completed the Company Directors Course at the Australian Institute of Company Directors in 2018.分析記事 • Dec 27A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share PriceWith a price-to-sales (or "P/S") ratio of 2.2x Cann Group Limited ( ASX:CAN ) may be sending very bullish signals at...お知らせ • Dec 04+ 1 more updateCann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023Cann Group Limited announced that its Chief Financial Officer Deborah Ambrosini, has resigned for personal reasons effective December 22, 2023.お知らせ • Nov 22+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,333 Price\Range: AUD 0.11268 Transaction Features: Subsequent Direct Listingお知らせ • Aug 29Cann Group Limited, Annual General Meeting, Oct 26, 2023Cann Group Limited, Annual General Meeting, Oct 26, 2023, at 10:00 AUS Eastern Standard Time.Reported Earnings • Aug 29Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$35m free cash flow). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$53.3m market cap, or US$34.2m).お知らせ • Jul 26Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 97,153,716 Price\Range: AUD 0.12 Discount Per Security: AUD 0.0024 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Jul 06Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023Cann Group Limited provided revenue guidance for the year ended June 30, 2023. Cann expects to report unaudited product sales revenue of approximately $13.5 million, before accounting for services, for the 12 months ending 30 June 2023 representing a 111% increase on FY22 revenue ($6.4 million). Strong market demand saw revenue from the sale of dried flower products increase by approximately 500% on FY22 and is the base for continued growth as the company scales up production. This improvement was driven by the domestic market, with the strong sales momentum supported by new clients entering into supply agreements, and several existing clients with repeat orders. Customer acquisition has been strengthened by Cann's ability to supply consistent quality, GMP product from the flagship facility in Mildura, achieved through state- of-the-art cultivation and manufacturing processes. FY23 production output at Mildura was 2.2 tonnes. In May 2023, Cann planted the largest crop in the Company's history, representing 8 tons annualised yield. This crop will be harvested in July 2023.分析記事 • May 18Cann Group (ASX:CAN) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Feb 25First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.お知らせ • Jan 20Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical TrailCann Group Limited announced preliminary results from their Phase 3 clinical trail. Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances. Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances. Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo. Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication. Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete.お知らせ • Jan 10Cann Group Limited Announces Chief Executive Officer ChangesCann Group Limited announced that Peter Koetsier has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on January 16, 2023. Mr. Koetsier will replace Peter Crock, who was appointed on April 19, 2016 and announced on October 24, 2022 that he would be stepping down as CEO of the Company. Mr. Koetsier brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK, and Bristol-Myers Squibb in Europe. Mr. Koetsier has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.お知らせ • Nov 21Cann Group Limited Announces Final Clinical Trial Participant Completes StudyCann Group Limited announced that the final participant enrolled into Cann Group's Phase III low-dose CBD clinical trial has attended their last study visit, and data entry for the trial has been completed. A total of 257 participants have completed the trial, exceeding the Company's initial target of 212. Study results are anticipated to be finalised early in the 2023 calendar year, shortly after which Cann expects to submit its formal drug registration application to the Therapeutic Goods Administration (TGA). The clinical trial is investigating the safety and efficacy of Cann's proprietary Satipharm CBD capsules for treating sleep disturbance. This forms part of the Company's strategy to register a low-dose CBD medicine for over-the-counter sale, making it available to consumers at pharmacies without requiring a prescription. On 6 April 2022 global healthcare company, GSK Consumer Healthcare (trading as Haleon), secured an exclusive evaluation and option agreement with Cann for the marketing and sale of over-the-counter Satipharm CBD capsules for Australia and potentially other markets globally. The parties subsequently agreed to and signed a non-binding commercial term sheet on 7 November 2022.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 28Cann Group Limited Appoints Julian John Chick as DirectorCann Group Limited appointed Julian John Chick as Director effective from October 26, 2022.お知らせ • Oct 24Cann Group Limited Announces Resignation of Peter Crock as CEOCann Group Limited announced that Chief Executive Officer, Peter Crock, has given notice of his resignation from the position as CEO. Mr. Crock will remain in the CEO role until a new CEO has been appointed. The Board will be initiating a search for a CEO immediately. Mr. Crock was appointed to the position of CEO prior to Cann Group being listed on the ASX in May of 2017.お知らせ • Oct 11Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep DisturbanceCann Group Limited announced that it has met its enrolment target for the Company's Phase III clinical trial of low-dose Satipharm CBD capsules for short-term sleep disturbance. In excess of 212 patients have been enrolled into the clinical trial, which commenced recruitment in February 2022 at trial centres in both Australia and New Zealand. The Company, in conjunction with its trial investigators, is now undertaking a follow-up analysis to determine if the participant numbers are adequate to detect statistical significance and provide a definitive study outcome. The Company anticipates that a favourable trial result will support the registration of Satipharm CBD capsules as a Schedule 3 over-the-counter medicine in Australia, making it available to patients without requiring a prescription. Cann Group will update the market with the results of the trial once they have been completed and analysed.お知らせ • Oct 03Cann Group Limited Announces Executive ChangesCann Group Limited announced that Ms Geraldine Farrell has resigned as Company Secretary effective 25 October 2022, after the Company's Annual General Meeting has concluded on that date. Cann also announced that Ms Deborah Ambrosini, the Company's Chief Financial Officer (CFO), will be appointed as Company Secretary following Ms Farrell's departure. Ms Ambrosini was appointed as CFO of Cann on 1 September 2022. In addition to her experience as a CFO in senior finance roles with ASX-listed companies, Ms Ambrosini brings significant experience as a company secretary, most recently as CFO and Company Secretary with Acrux Limited.お知らせ • Sep 20Cann Group Limited Appoints Robert Barnes & Julian Chick to the BoardCann Group Limited announced that Mr. Robert Barnes and Dr. Julian Chick will be appointed to the Board of Directors to fill casual vacancies. Mr. Barnes' appointment will take effect immediately, with Mr. Barnes being eligible for re-election at the Company's upcoming Annual General Meeting (AGM) to be held on 25 October 2022. Dr. Chick's appointment will take effect on 26 October 2022. Mr. Barnes is an experienced senior executive who has delivered extensive leadership and operational outcomes across a wide variety of healthcare industries, including pharmaceutical, nutraceutical, infant formula, consumer, medical devices, and diagnostics. He has an applied science degree in Medical Science, a MBA, and is a Graduate of the Australian Institute of Company Directors. Having worked both globally and in Australia in leading commercial healthcare organisations, he brings substantial and diverse commercial and scientific understanding to the Company. Dr. Chick has over 25 years of experience in the biotechnology and medical technology sectors, as well as in investment banking. He has worked with both public and private companies, bringing a number of technologies through from discovery to market, as well as experience in capital raisings, company restructuring, licensing, business development and M&A transactions. He has a PhD from La Trobe University /Oxford University. Mr. Barnes has held senior executive roles at several pharmaceutical and consumer healthcare entities including Aspen Pharmacare Australia Pty Ltd, Sanofi Australia, and Mayne Group. Mr. Barnes has also served on the board of the peak OTC industry body being Consumer Healthcare Products Australia. He has experience in the medicinal cannabis sector, being a former member of the advisory board to Leafcann Group Pty Ltd. Dr. Chick has held senior executive roles and directorships at several Australian and international life science companies, both listed and private, including Avexa Ltd, Opyl Ltd. and Admedus Ltd.お知らせ • Sep 01Cann Group Limited Announces Resignation of John Sharman as DirectorCann Group Limited announced that John Sharman has resigned as a director of the company effective 1 September 2022 due to his other business commitments. Mr. Sharman was appointed to the Board of the Company on 27 April 2021. As part of its ongoing review process, the Board is underway with the identification and appointment of a new director.お知らせ • Aug 30Cann Group Limited, Annual General Meeting, Oct 25, 2022Cann Group Limited, Annual General Meeting, Oct 25, 2022, at 10:00 AUS Eastern Standard Time.Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).お知らせ • Jun 30Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic GoodsCann Group Limited announced that the Therapeutic Goods Administration (TGA) has granted Cann a GMP licence to manufacture therapeutic goods which includes GMP testing at its Mildura facility (Mildura GMP Licence). In combination with the licences and permits issued by the Office of Drug Control (ODC) earlier this year, the Mildura GMP Licence enables Cann to manufacture Active Pharmaceutical Ingredients (API) and hard capsules, and to conduct GMP-approved activities at the facility's existing chemistry and microbiology laboratories. This will allow the Company to produce API at the facility, manufacture Satipharm capsules for human therapeutic use, and perform in-house chemical, physical, and microbiological tests to demonstrate that products meet local and overseas regulatory requirements. While manufacturing and testing activities had already commenced at Mildura following thelicences and permits issued by the ODC and the Victorian Department of Health, the Mildura GMP Licence will allow medicinal cannabis products manufactured at Mildura to be made available to patients via the TGA's approved access pathways in Australia and (subject to approvals) for export markets.お知らせ • Jun 02Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund ProgramCann Group Limited announced that it received the second milestone payment from the Victorian government's Regional Jobs Fund program. The company was approved for the fund in 2020 which is worth $1.975 million in total. The funds are paid over three milestone periods, with the most recent payment of $0.5 million being received on June 1, 2022, in recognition of the company meeting the necessary requirements. The payment has been received in the same week that a media release from the Victorian Premier's office highlighted the current level of government support being provided to the company at its Mildura facility.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 07Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group LimitedCann Group Limited announced that the Office of Drug Control (ODC) has granted Cann the necessary permit to allow the manufacture of medicinal cannabis products at its Mildura facility. Cann will utilise this permit for its extraction suite on site. This permit was foreshadowed in an earlier announcement on 15 March 2022, regarding the issue of a permit to allow cultivation and production of medicinal cannabis and research activities in relation to medicinal cannabis. The manufacturing permit now completes the suite of ODC permits required for the operation of its Mildura facility. Cann is also continuing to work with the Therapeutic Goods Administration on the GMP licence application for the Mildura site and Cann expects to have that licence in place in coming months. The extracts that Cann will produce at the Mildura facility will be used to formulate medicinal cannabis products for Cann's customers for supply within Australia and overseas. Additionally, Cann is authorised to sell extracts as an Active Pharmaceutical Ingredient (API).Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.028 loss per share (up from AU$0.05 loss in 1H 2021). Net loss: AU$8.28m (loss narrowed 12% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 277%, compared to a 713% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 17Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive DirectorCann Group Limited announced that Mr. Geoffrey Pearce has resigned as a non-executive director of the Company, effective 17 February 2022, due to his other board and executive commitments. Mr. Pearce was appointed to the Board of the Company on 11 April 2016 and was subsequently re-elected at the 2017 Annual General Meeting, and then again at the 2020 Annual General Meeting.お知らせ • Feb 15Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical TrialCann Group Limited announced that it will begin recruiting patients next month for a phase 3 clinical trial examining the efficacy of its proprietary CBD-Satipharm capsule for the short-term treatment of sleep disturbances and quality of life outcomes. The clinical trial is a randomised, double blind, placebo-controlled study and part of a registration program undertaken by Cann to secure an Australian approval for a Schedule 3 (S3) over-the-counter cannabidiol (CBD) product. At least 212 patients will be randomly placed into four cohorts receiving one of three different doses of the Satipharm CBD formulation, or a placebo. Clinical trial sites will be in most major capital cities in Australia. Patients will be treated for four weeks, and results of the trial are anticipated to be released later in 2022, in line with Cann's S3 registration program. Earlier clinical trials involving Satipharm CBD capsules have been successful; a previous phase 1 clinical trial of the Satipharm CBD capsules demonstrated the safety and high performance of the oral capsule technology, including the superior absorption of CBD by trial subjects compared to the leading medical cannabis product in the market,1 and a phase 2 clinical trial of the Satipharm CBD capsules showed them to be efficacious as an add-on therapy in the treatment of paediatric, intractable epilepsy. During the 2021 financial year, Australians spent approximately $97 million on pharmacy-supplied over-the-counter sleep disturbance products. Dr. Dev Banerjee, a leading sleep and cannabinoid physician in Australia who, with other sleep specialists, has assisted with the clinical trial design, said while strong anecdotal evidence exists to support the efficacy of CBD for patients struggling to achieve sleep, it is extremely important that this is validated by well-designed clinical trials. The Satipharm CBD capsules will be produced at Cann's new manufacturing facility near Mildura which has recently been audited by the TGA as part of the process to obtain a GMP licence for that facility.分析記事 • Nov 03Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For NowThe underwhelming share price performance of Cann Group Limited ( ASX:CAN ) in the past three years would have...Executive Departure • Sep 07Chief Financial Officer Greg Bullock has left the companyDuring their tenure, earnings grew by 46% annually compared to the industry average of 17%. On the 1st of September, Greg Bullock left the company after 1.3 in the role. We don't have any record of a personal shareholding under Greg's name. Greg is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)Full year 2021 results: Net loss: AU$25.1m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.お知らせ • May 28Cann Group Limited Revises Revenue Guidance for the Year 2021Cann Group Limited revised revenue guidance for the year 2021. With revenue of $3.2 million so far this financial year (up to the end of April), the company is now forecasting total revenue for the year 2021 of between $4 million and $5 million compared to the previous revised guidance announced 15 February 2021 of between $8 million and $10 million. The revenue guidance adjustment reflects an update to the expected timing of revenue only, with the balance of the 2021 original forecast revenue now expected to be received in 2022.お知らせ • Mar 11Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million on February 14, 2021. As per the transaction, Cann Group will issue 4.3 million new Cann shares to the value of CAD 2.5 million at completion to Harvest One and and conditional deferred consideration of up to CAD 1.5 million based on achieving agreed operational and financial results and to be paid in new Cann shares or cash at the election of Cann. The number of new Cann shares to be issued to Harvest One at completion will be based on the value of the AUD equivalent of CAD 2.5 million at Completion at an issue price per share to be based on the VWAP of Cann’s shares during the 5 full trading days on the ASX ending on the ASX trading day immediately prior to the date on which completion occurs. In addition to customary terms for a transaction of this nature, the acquisition terms include the satisfaction of certain conditions precedent, including obtaining all necessary regulatory and third-party approvals and consents. The transaction is expected to be completed in March 2021, with the final element of the conditional deferred consideration expected to be paid by September 2021. Moelis Australia acted as financial advisor and William Ross Lawyers & Advisers acted as legal advisor to Cann Group. Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT) on March 10, 2021.お知らせ • Mar 09Cann Group Limited, Olivia Newton-John Cancer Research Institute and Austin Health Partnered in A Clinical Tria to Assess Medicinal Cannabis for Symptom Management in People with Advanced CancerCann Group Limited and the Olivia Newton-John Cancer Research Institute (ONJCRI), as the La Trobe School of Cancer Medicine, and Austin Health, announced that they have partnered in a clinical trial to assess medicinal cannabis for symptom management in people with advanced cancer. The Phase I trial commenced in late September 2020 and trial outcomes are currently being reviewed, with patients having tolerated the treatment well to date. Phase I is focused on the titration and safety of administering this new formulation of medicinal cannabis in a controlled manner. Should the Phase I study demonstrate safety and tolerability of the drug, Phase II (a double blind, randomised, placebo-controlled trial) will see the enrolment of 108 participants with advanced cancers, subject to meeting trial specific eligibility criteria. The Phase II study will evaluate the efficacy of the drug by assessing global Quality of Life in these participants, as well as other domains including pain, anorexia, nausea, anxiety and sleep. Participants can only be referred to the study by their treating physician.お知らせ • Mar 03+ 1 more updateCann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT) on February 16, 2021. The aggregate 0.004 million shares will be issued by Cann Group Limited (ASX:CAN) for the transactions.Reported Earnings • Feb 24First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)First half 2021 results: Net loss: AU$9.40m (loss widened 12% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year and the company’s share price has also fallen by 41% per year.分析記事 • Feb 23Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • Feb 16+ 1 more updateCann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million on February 15, 2021. As per the transaction, Cann Group will issue new Cann shares to the value of CAD 2.5 million at completion to Harvest One and and conditional deferred consideration of up to CAD 1.5 million based on achieving agreed operational and financial results and to be paid in new Cann shares or cash at the election of Cann. The number of new Cann shares to be issued to Harvest One at completion will be based on the value of the AUD equivalent of CAD 2.5 million at Completion at an issue price per share to be based on the VWAP of Cann’s shares during the 5 full trading days on the ASX ending on the ASX trading day immediately prior to the date on which completion occurs. In addition to customary terms for a transaction of this nature, the acquisition terms include the satisfaction of certain conditions precedent, including obtaining all necessary regulatory and third-party approvals and consents. The transaction is expected to be completed in March 2021, with the final element of the conditional deferred consideration expected to be paid by September 2021. Moelis Australia acted as financial advisor and William Ross Lawyers & Advisers acted as legal advisor to Cann Group.Is New 90 Day High Low • Feb 09New 90-day high: AU$0.78The company is up 144% from its price of AU$0.32 on 11 November 2020. The Australian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 29% over the same period.Price Target Changed • Jan 08Price target lowered to AU$1.12Down from AU$1.87, the current price target is provided by 1 analyst. The new target price is 76% above the current share price of AU$0.64. As of last close, the stock is down 33% over the past year.お知らせ • Jan 06Cann Group Limited Receives Initial 19,000 Unit Order for EuropeCann Group Limited announced that it has committed to a minority investment in iuvo Therapeutics Limited and has received an initial order to ship 19,000 units of 30ml extract. Cann Group has made a strategic CAD 1 million cornerstone commitment in a CAD5 million capital raising that is currently being completed by iuvo, resulting in Cann Group holding approximately 2% of iuvo's issued ordinary shares. Funds raised will be used by iuvo to expand sales and marketing capabilities and assist with construction of a new manufacturing and formulation facility in Malta. Following the investment, Cann Group will be granted exclusive external rights to supply iuvo Therapeutics GmbH, iuvo's wholly-owned subsidiary, (`iuvo Germany'), with medicinal cannabis extracts until 31 December 2021, with those rights then converting to preferred non-exclusive status. iuvo has placed an initial 19,000 unit order for Cann product which is expected to be shipped to Germany within the next month, subject to relevant regulatory clearances. Being fully compliant with the latest German monograph addition "Cannabis Extractum Normatum", it will be one of the first full-spectrum extracts available in the market.分析記事 • Nov 25What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?Cann Group Limited (ASX:CAN) shareholders will doubtless be very grateful to see the share price up 77% in the last...分析記事 • Nov 25One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To BeMarket forces rained on the parade of Cann Group Limited (ASX:CAN) shareholders today, when the covering analyst...Major Estimate Revision • Nov 25Analysts update estimatesThe 2021 consensus revenue estimate was lowered from AU$16.0m to AU$14.0m. Earning per share (EPS) estimate was unchanged from the last update at -AU$0.04. The Pharmaceuticals industry in Australia is expected to see an average net income growth of 21% next year. The consensus price target was lowered from AU$1.87 to AU$1.86. Share price is up 77% to AU$0.55 over the past week.Is New 90 Day High Low • Nov 24New 90-day high: AU$0.51The company is up 22% from its price of AU$0.41 on 26 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Recent Insider Transactions • Oct 20Deputy Chairman recently bought AU$55k worth of stockOn the 13th of October, Philip Robert Jacobsen bought around 144k shares on-market at roughly AU$0.38 per share. In the last 3 months, they made an even bigger purchase worth AU$79k. Philip Robert has been a buyer over the last 12 months, purchasing a net total of AU$156k worth in shares.お知らせ • Oct 13An unknown buyers acquired 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB).An unknown buyers acquired 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB) on October 9, 2020. Aurora has indicated to Cann Group that its decision to exit a strategic holding in Cann Group. The transaction will not have any impact on Cann Group’s business plans. An unknown buyers completed the acquisition of 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB) on October 9, 2020Is New 90 Day High Low • Oct 12New 90-day low: AU$0.38The company is down 54% from its price of AU$0.82 on 14 July 2020. The Australian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.お知らせ • Sep 21Cann Group Limited(ASX:CAN) dropped from S&P Global BMI IndexCann Group Limited(ASX:CAN) dropped from S&P Global BMI Indexお知らせ • Aug 19Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 25.9 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 25.9 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 64,750,000 Price\Range: AUD 0.4 Discount Per Security: AUD 0.012お知らせ • Jul 24Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 14.3 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 14.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 35,750,000 Price\Range: AUD 0.4 Discount Per Security: AUD 0.008 Transaction Features: Subsequent Direct Listing株主還元CANAU PharmaceuticalsAU 市場7D-20.0%-0.1%-0.3%1Y-71.4%-18.2%1.8%株主還元を見る業界別リターン: CAN過去 1 年間で-18.2 % の収益を上げたAustralian Pharmaceuticals業界を下回りました。リターン対市場: CANは、過去 1 年間で1.8 % のリターンを上げたAustralian市場を下回りました。価格変動Is CAN's price volatile compared to industry and market?CAN volatilityCAN Average Weekly Movement19.9%Pharmaceuticals Industry Average Movement10.4%Market Average Movement10.2%10% most volatile stocks in AU Market17.3%10% least volatile stocks in AU Market4.2%安定した株価: CANの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CANの weekly volatility ( 20% ) は過去 1 年間安定していますが、依然としてAustralianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014n/an/awww.canngrouplimited.comキャン・グループ・リミテッドは、その子会社とともに、オーストラリアとヨーロッパで薬用大麻の育種、栽培、製造、販売に従事している。同社の製品ポートフォリオには、カンナビノイドのサティファーマ・デリバリー・システムが含まれる。同社は2014年に設立され、オーストラリアのミルデューラを拠点としている。もっと見るCann Group Limited 基礎のまとめCann Group の収益と売上を時価総額と比較するとどうか。CAN 基礎統計学時価総額AU$6.50m収益（TTM）AU$14.73m売上高(TTM)AU$11.31m0.4xPER（株価収益率0.6xP/SレシオCAN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CAN 損益計算書（TTM）収益AU$11.31m売上原価AU$6.15m売上総利益AU$5.16mその他の費用-AU$9.57m収益AU$14.73m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.0091グロス・マージン45.61%純利益率130.29%有利子負債／自己資本比率43.5%CAN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 20:14終値2026/05/29 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cann Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Cameron BellCanaccord GenuityPaul JenszPAC Partners Securities Pty. Ltd.
New Risk • Mar 04New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (32% accrual ratio). Shareholders have been substantially diluted in the past year (191% increase in shares outstanding). Market cap is less than US$10m (AU$11.1m market cap, or US$7.86m).
お知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australia
お知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069
Reported Earnings • Sep 30Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.
New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 24% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.8m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$2.8m). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (AU$11.9m market cap, or US$7.87m).
New Risk • Mar 04New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (22% average weekly change). High level of non-cash earnings (32% accrual ratio). Shareholders have been substantially diluted in the past year (191% increase in shares outstanding). Market cap is less than US$10m (AU$11.1m market cap, or US$7.86m).
お知らせ • Dec 05Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 6.5 million. Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 120,395,238 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Security Name: Ordinay Shares Security Type: Common Stock Securities Offered: 444,822,153 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069 Transaction Features: Subsequent Direct Listing
お知らせ • Oct 29Cann Group Limited, Annual General Meeting, Nov 28, 2025Cann Group Limited, Annual General Meeting, Nov 28, 2025. Location: hwl ebsworth lawyers, level 8, 447 collins street, melbourne, vic 3000, melbourne Australia
お知らせ • Oct 27+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 217,391,304 Price\Range: AUD 0.0115 Discount Per Security: AUD 0.00069
Reported Earnings • Sep 30Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 60% per year, which means it is significantly lagging earnings.
New Risk • Sep 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 24% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.8m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$2.8m). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Market cap is less than US$10m (AU$11.9m market cap, or US$7.87m).
New Risk • Aug 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$9.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$9.8m free cash flow). Negative equity (-AU$2.8m). Earnings have declined by 16% per year over the past 5 years. Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Market cap is less than US$10m (AU$9.12m market cap, or US$5.97m). Minor Risk Share price has been volatile over the past 3 months (17% average weekly change).
Reported Earnings • Aug 31Full year 2025 earnings released: AU$0.042 loss per share (vs AU$0.12 loss in FY 2024)Full year 2025 results: AU$0.042 loss per share (improved from AU$0.12 loss in FY 2024). Revenue: AU$13.3m (down 28% from FY 2024). Net loss: AU$22.3m (loss narrowed 56% from FY 2024).
分析記事 • Jul 20Cann Group Limited's (ASX:CAN) Share Price Boosted 36% But Its Business Prospects Need A Lift TooCann Group Limited ( ASX:CAN ) shareholders are no doubt pleased to see that the share price has bounced 36% in the...
お知らせ • Jul 02+ 1 more updateCann Group Limited Announces Appointment of Jenni Pilcher as Permanent Managing Director Contract RenewedCann Group Limited announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of Managing Director (New Employment Contract). This follows the Company's previous announcement, made on the 15 July 2024, relating to the appointment of Ms. Jenni Pilcher as Managing Director, on a fixed-term contract which ended 1 July 2025 (Previous Employment Contract). With the exception of the contract term (now a permanent position requiring four (4) months' notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.
分析記事 • Jun 02Investors Aren't Buying Cann Group Limited's (ASX:CAN) RevenuesCann Group Limited's ( ASX:CAN ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy right now...
New Risk • Apr 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (AU$9.65m market cap, or US$6.17m). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
New Risk • Apr 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 23% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (AU$10.2m market cap, or US$6.58m).
お知らせ • Apr 14Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Apr 08Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.711902 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 41,876,573 Price\Range: AUD 0.017 Discount Per Security: AUD 0.00102 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (AU$13.4m market cap, or US$8.56m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Shareholders have been diluted in the past year (22% increase in shares outstanding).
お知らせ • Mar 12Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.105 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: AUD 0.015 Transaction Features: Subsequent Direct Listing
New Risk • Feb 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$16.1m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (AU$16.1m market cap, or US$9.89m). Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).
分析記事 • Jan 31The Market Doesn't Like What It Sees From Cann Group Limited's (ASX:CAN) Revenues YetCann Group Limited's ( ASX:CAN ) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now...
お知らせ • Dec 06Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 2.255994 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,724,489 Price\Range: AUD 0.04 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,675,343 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Oct 09Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 156,312,161 Price\Range: AUD 0.04 Security Features: Attached Options Transaction Features: Rights Offering
分析記事 • Sep 24Cann Group Limited's (ASX:CAN) Price Is Right But Growth Is Lacking After Shares Rocket 36%Despite an already strong run, Cann Group Limited ( ASX:CAN ) shares have been powering on, with a gain of 36% in the...
お知らせ • Sep 03Cann Group Limited, Annual General Meeting, Oct 28, 2024Cann Group Limited, Annual General Meeting, Oct 28, 2024.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)Full year 2024 results: AU$0.12 loss per share (further deteriorated from AU$0.091 loss in FY 2023). Revenue: AU$19.1m (down 7.6% from FY 2023). Net loss: AU$51.2m (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
お知らせ • Jul 24Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024Cann Group Limited announced that they will report fiscal year 2024 results on Aug 30, 2024
お知らせ • Jul 15+ 1 more updateCann Group Limited Appoints Jenni Pilcher as Managing DirectorCann Group Limited announced that it has executed an employment agreement to formally appoint Ms. Jenni Pilcher to the role of CEO & Managing Director. Jenni joined Cann as a Non-executive Director on 15 September 2020. In February 2024, Jenni stepped into an Executive Director role to provide financial oversight of the Company, transitioning to Interim CEO following the notice of resignation of the CEO on 21 March 2024. Chairman, Julian Chick, commented: "Since stepping in as Executive Director in February, Jenni has implemented a restructure and cost savings plan which will generate at least $2.15 million savings per annum. Following on from this, Jenni successfully managed the re-release of the Company's half-year financial report in May accompanied by an audit review report free from disclaimers, secured a further $5 million debt to fund the business, and achieved the ASX's reinstatement of CAN securities to trading in June. Jenni has over 15 years of senior finance executive experience in the medical, biotechnology and technology sectors, within small-mid cap ASX-listed companies. In addition to financial management, investor relations and corporate governance experience, Jenni has successfully completed multiple capital raisings and M&A transactions, including company acquisitions, asset sales, and a takeover defense. Most recently, Jenni was Chief Financial Officer & Company Secretary of technology communications company Whispir Ltd, and prior to that was CFO & Company Secretary of digital imaging company, Mach7 Technologies. She has also previously held CFO roles with Australia biotechnology companies Alchemia Limited and Mesoblast Limited. Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand. Ms. Pilcher will be appointed for a fixed term ending on 1 July 2025, subject to termination by either party. The fixed term can be extended at any time by mutual agreement, in writing, between Ms. Pilcher and the Company.
Board Change • Jun 05Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Jun 04Cann Group Limited's (ASX:CAN) Low P/S No Reason For ExcitementWith a price-to-sales (or "P/S") ratio of 1x Cann Group Limited ( ASX:CAN ) may be sending very bullish signals at the...
New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$20m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$20m free cash flow). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (AU$27.1m market cap, or US$17.6m).
お知らせ • Jan 08+ 1 more updateCann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory AffairsCann Group Limited announced that Tony Di Pietro will act as joint Company Secretary with Steven Notaro, Head of Legal and Regulatory Affairs at Cann Group. . Having spent the past two decades at ASX-listed companies, Mr. Di Pietro boasts extensive experience as CFO/Company Secretary in the med-tech industry, with his last three roles at Sienna Cancer Diagnostics Limited (November 2014 - July 2020), INOVIQ Limited (July 2020 - November 2022) and Genetic Technologies Limited (November 2022 - present). In his most recent role at Genetic Technologies, Mr. Di Pietro managed a capital raising of $5 million from US-based investors and was responsible for both US and Australian due diligence activities and compliance with both ASX/Corporations Act & NASDAQ/SEC regulations. Mr. Di Pietro's qualifications include: A Bachelor of Commerce (BCom),Accounting and Finance, from Swinburne University of Technology;Chartered Accountants (CA) accreditation (1989-2000); Graduate Diploma of Applied Corporate Governancefrom the Governance Institute of Australia(2012-2014); and Completed the Company Directors Course at the Australian Institute of Company Directors in 2018.
分析記事 • Dec 27A Piece Of The Puzzle Missing From Cann Group Limited's (ASX:CAN) Share PriceWith a price-to-sales (or "P/S") ratio of 2.2x Cann Group Limited ( ASX:CAN ) may be sending very bullish signals at...
お知らせ • Dec 04+ 1 more updateCann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023Cann Group Limited announced that its Chief Financial Officer Deborah Ambrosini, has resigned for personal reasons effective December 22, 2023.
お知らせ • Nov 22+ 1 more updateCann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 3,333,333 Price\Range: AUD 0.11268 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 29Cann Group Limited, Annual General Meeting, Oct 26, 2023Cann Group Limited, Annual General Meeting, Oct 26, 2023, at 10:00 AUS Eastern Standard Time.
Reported Earnings • Aug 29Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)Full year 2023 results: AU$0.091 loss per share (further deteriorated from AU$0.079 loss in FY 2022). Revenue: AU$21.7m (up 93% from FY 2022). Net loss: AU$33.8m (loss widened 28% from FY 2022). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
New Risk • Aug 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$35m free cash flow). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (AU$53.3m market cap, or US$34.2m).
お知らせ • Jul 26Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 97,153,716 Price\Range: AUD 0.12 Discount Per Security: AUD 0.0024 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Jul 06Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023Cann Group Limited provided revenue guidance for the year ended June 30, 2023. Cann expects to report unaudited product sales revenue of approximately $13.5 million, before accounting for services, for the 12 months ending 30 June 2023 representing a 111% increase on FY22 revenue ($6.4 million). Strong market demand saw revenue from the sale of dried flower products increase by approximately 500% on FY22 and is the base for continued growth as the company scales up production. This improvement was driven by the domestic market, with the strong sales momentum supported by new clients entering into supply agreements, and several existing clients with repeat orders. Customer acquisition has been strengthened by Cann's ability to supply consistent quality, GMP product from the flagship facility in Mildura, achieved through state- of-the-art cultivation and manufacturing processes. FY23 production output at Mildura was 2.2 tonnes. In May 2023, Cann planted the largest crop in the Company's history, representing 8 tons annualised yield. This crop will be harvested in July 2023.
分析記事 • May 18Cann Group (ASX:CAN) Is Making Moderate Use Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Feb 25First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)First half 2023 results: AU$0.053 loss per share (further deteriorated from AU$0.028 loss in 1H 2022). Net loss: AU$18.8m (loss widened 128% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
お知らせ • Jan 20Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical TrailCann Group Limited announced preliminary results from their Phase 3 clinical trail. Trial compared the efficacy of low dose Satipharm® CBD capsules to placebo in treating sleep disturbances. Three doses of Satipharm® CBD capsules were compared to placebo in a randomised, double-blind, placebo-controlled, multicentre clinical trial that included a total of 257 participants with sleep disturbances. Preliminary view of the analysis of the primary end-points have not shown a statistically superior response compared to placebo. Cann Group expects these trial results will delay submission of the registration application to the Therapeutic Goods Administration (TGA) for this indication. Once the full data set (including the secondary end-points) and report of the clinical trial is delivered to the company, Cann Group will evaluate the data and review its approach for this indication. A market update will be published once that review is complete.
お知らせ • Jan 10Cann Group Limited Announces Chief Executive Officer ChangesCann Group Limited announced that Peter Koetsier has been appointed to the role of Chief Executive Officer (CEO) and will commence in the role on January 16, 2023. Mr. Koetsier will replace Peter Crock, who was appointed on April 19, 2016 and announced on October 24, 2022 that he would be stepping down as CEO of the Company. Mr. Koetsier brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies. He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK, and Bristol-Myers Squibb in Europe. Mr. Koetsier has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.
お知らせ • Nov 21Cann Group Limited Announces Final Clinical Trial Participant Completes StudyCann Group Limited announced that the final participant enrolled into Cann Group's Phase III low-dose CBD clinical trial has attended their last study visit, and data entry for the trial has been completed. A total of 257 participants have completed the trial, exceeding the Company's initial target of 212. Study results are anticipated to be finalised early in the 2023 calendar year, shortly after which Cann expects to submit its formal drug registration application to the Therapeutic Goods Administration (TGA). The clinical trial is investigating the safety and efficacy of Cann's proprietary Satipharm CBD capsules for treating sleep disturbance. This forms part of the Company's strategy to register a low-dose CBD medicine for over-the-counter sale, making it available to consumers at pharmacies without requiring a prescription. On 6 April 2022 global healthcare company, GSK Consumer Healthcare (trading as Haleon), secured an exclusive evaluation and option agreement with Cann for the marketing and sale of over-the-counter Satipharm CBD capsules for Australia and potentially other markets globally. The parties subsequently agreed to and signed a non-binding commercial term sheet on 7 November 2022.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 28Cann Group Limited Appoints Julian John Chick as DirectorCann Group Limited appointed Julian John Chick as Director effective from October 26, 2022.
お知らせ • Oct 24Cann Group Limited Announces Resignation of Peter Crock as CEOCann Group Limited announced that Chief Executive Officer, Peter Crock, has given notice of his resignation from the position as CEO. Mr. Crock will remain in the CEO role until a new CEO has been appointed. The Board will be initiating a search for a CEO immediately. Mr. Crock was appointed to the position of CEO prior to Cann Group being listed on the ASX in May of 2017.
お知らせ • Oct 11Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep DisturbanceCann Group Limited announced that it has met its enrolment target for the Company's Phase III clinical trial of low-dose Satipharm CBD capsules for short-term sleep disturbance. In excess of 212 patients have been enrolled into the clinical trial, which commenced recruitment in February 2022 at trial centres in both Australia and New Zealand. The Company, in conjunction with its trial investigators, is now undertaking a follow-up analysis to determine if the participant numbers are adequate to detect statistical significance and provide a definitive study outcome. The Company anticipates that a favourable trial result will support the registration of Satipharm CBD capsules as a Schedule 3 over-the-counter medicine in Australia, making it available to patients without requiring a prescription. Cann Group will update the market with the results of the trial once they have been completed and analysed.
お知らせ • Oct 03Cann Group Limited Announces Executive ChangesCann Group Limited announced that Ms Geraldine Farrell has resigned as Company Secretary effective 25 October 2022, after the Company's Annual General Meeting has concluded on that date. Cann also announced that Ms Deborah Ambrosini, the Company's Chief Financial Officer (CFO), will be appointed as Company Secretary following Ms Farrell's departure. Ms Ambrosini was appointed as CFO of Cann on 1 September 2022. In addition to her experience as a CFO in senior finance roles with ASX-listed companies, Ms Ambrosini brings significant experience as a company secretary, most recently as CFO and Company Secretary with Acrux Limited.
お知らせ • Sep 20Cann Group Limited Appoints Robert Barnes & Julian Chick to the BoardCann Group Limited announced that Mr. Robert Barnes and Dr. Julian Chick will be appointed to the Board of Directors to fill casual vacancies. Mr. Barnes' appointment will take effect immediately, with Mr. Barnes being eligible for re-election at the Company's upcoming Annual General Meeting (AGM) to be held on 25 October 2022. Dr. Chick's appointment will take effect on 26 October 2022. Mr. Barnes is an experienced senior executive who has delivered extensive leadership and operational outcomes across a wide variety of healthcare industries, including pharmaceutical, nutraceutical, infant formula, consumer, medical devices, and diagnostics. He has an applied science degree in Medical Science, a MBA, and is a Graduate of the Australian Institute of Company Directors. Having worked both globally and in Australia in leading commercial healthcare organisations, he brings substantial and diverse commercial and scientific understanding to the Company. Dr. Chick has over 25 years of experience in the biotechnology and medical technology sectors, as well as in investment banking. He has worked with both public and private companies, bringing a number of technologies through from discovery to market, as well as experience in capital raisings, company restructuring, licensing, business development and M&A transactions. He has a PhD from La Trobe University /Oxford University. Mr. Barnes has held senior executive roles at several pharmaceutical and consumer healthcare entities including Aspen Pharmacare Australia Pty Ltd, Sanofi Australia, and Mayne Group. Mr. Barnes has also served on the board of the peak OTC industry body being Consumer Healthcare Products Australia. He has experience in the medicinal cannabis sector, being a former member of the advisory board to Leafcann Group Pty Ltd. Dr. Chick has held senior executive roles and directorships at several Australian and international life science companies, both listed and private, including Avexa Ltd, Opyl Ltd. and Admedus Ltd.
お知らせ • Sep 01Cann Group Limited Announces Resignation of John Sharman as DirectorCann Group Limited announced that John Sharman has resigned as a director of the company effective 1 September 2022 due to his other business commitments. Mr. Sharman was appointed to the Board of the Company on 27 April 2021. As part of its ongoing review process, the Board is underway with the identification and appointment of a new director.
お知らせ • Aug 30Cann Group Limited, Annual General Meeting, Oct 25, 2022Cann Group Limited, Annual General Meeting, Oct 25, 2022, at 10:00 AUS Eastern Standard Time.
Reported Earnings • Aug 30Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)Full year 2022 results: AU$0.079 loss per share. Revenue: AU$11.2m (up 32% from FY 2021). Net loss: AU$26.5m (loss widened 5.4% from FY 2021).
お知らせ • Jun 30Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic GoodsCann Group Limited announced that the Therapeutic Goods Administration (TGA) has granted Cann a GMP licence to manufacture therapeutic goods which includes GMP testing at its Mildura facility (Mildura GMP Licence). In combination with the licences and permits issued by the Office of Drug Control (ODC) earlier this year, the Mildura GMP Licence enables Cann to manufacture Active Pharmaceutical Ingredients (API) and hard capsules, and to conduct GMP-approved activities at the facility's existing chemistry and microbiology laboratories. This will allow the Company to produce API at the facility, manufacture Satipharm capsules for human therapeutic use, and perform in-house chemical, physical, and microbiological tests to demonstrate that products meet local and overseas regulatory requirements. While manufacturing and testing activities had already commenced at Mildura following thelicences and permits issued by the ODC and the Victorian Department of Health, the Mildura GMP Licence will allow medicinal cannabis products manufactured at Mildura to be made available to patients via the TGA's approved access pathways in Australia and (subject to approvals) for export markets.
お知らせ • Jun 02Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund ProgramCann Group Limited announced that it received the second milestone payment from the Victorian government's Regional Jobs Fund program. The company was approved for the fund in 2020 which is worth $1.975 million in total. The funds are paid over three milestone periods, with the most recent payment of $0.5 million being received on June 1, 2022, in recognition of the company meeting the necessary requirements. The payment has been received in the same week that a media release from the Victorian Premier's office highlighted the current level of government support being provided to the company at its Mildura facility.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Doug Rathbone was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 07Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group LimitedCann Group Limited announced that the Office of Drug Control (ODC) has granted Cann the necessary permit to allow the manufacture of medicinal cannabis products at its Mildura facility. Cann will utilise this permit for its extraction suite on site. This permit was foreshadowed in an earlier announcement on 15 March 2022, regarding the issue of a permit to allow cultivation and production of medicinal cannabis and research activities in relation to medicinal cannabis. The manufacturing permit now completes the suite of ODC permits required for the operation of its Mildura facility. Cann is also continuing to work with the Therapeutic Goods Administration on the GMP licence application for the Mildura site and Cann expects to have that licence in place in coming months. The extracts that Cann will produce at the Mildura facility will be used to formulate medicinal cannabis products for Cann's customers for supply within Australia and overseas. Additionally, Cann is authorised to sell extracts as an Active Pharmaceutical Ingredient (API).
Reported Earnings • Feb 21First half 2022 earnings: Revenues and EPS in line with analyst expectationsFirst half 2022 results: AU$0.028 loss per share (up from AU$0.05 loss in 1H 2021). Net loss: AU$8.28m (loss narrowed 12% from 1H 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 277%, compared to a 713% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 17Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive DirectorCann Group Limited announced that Mr. Geoffrey Pearce has resigned as a non-executive director of the Company, effective 17 February 2022, due to his other board and executive commitments. Mr. Pearce was appointed to the Board of the Company on 11 April 2016 and was subsequently re-elected at the 2017 Annual General Meeting, and then again at the 2020 Annual General Meeting.
お知らせ • Feb 15Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical TrialCann Group Limited announced that it will begin recruiting patients next month for a phase 3 clinical trial examining the efficacy of its proprietary CBD-Satipharm capsule for the short-term treatment of sleep disturbances and quality of life outcomes. The clinical trial is a randomised, double blind, placebo-controlled study and part of a registration program undertaken by Cann to secure an Australian approval for a Schedule 3 (S3) over-the-counter cannabidiol (CBD) product. At least 212 patients will be randomly placed into four cohorts receiving one of three different doses of the Satipharm CBD formulation, or a placebo. Clinical trial sites will be in most major capital cities in Australia. Patients will be treated for four weeks, and results of the trial are anticipated to be released later in 2022, in line with Cann's S3 registration program. Earlier clinical trials involving Satipharm CBD capsules have been successful; a previous phase 1 clinical trial of the Satipharm CBD capsules demonstrated the safety and high performance of the oral capsule technology, including the superior absorption of CBD by trial subjects compared to the leading medical cannabis product in the market,1 and a phase 2 clinical trial of the Satipharm CBD capsules showed them to be efficacious as an add-on therapy in the treatment of paediatric, intractable epilepsy. During the 2021 financial year, Australians spent approximately $97 million on pharmacy-supplied over-the-counter sleep disturbance products. Dr. Dev Banerjee, a leading sleep and cannabinoid physician in Australia who, with other sleep specialists, has assisted with the clinical trial design, said while strong anecdotal evidence exists to support the efficacy of CBD for patients struggling to achieve sleep, it is extremely important that this is validated by well-designed clinical trials. The Satipharm CBD capsules will be produced at Cann's new manufacturing facility near Mildura which has recently been audited by the TGA as part of the process to obtain a GMP licence for that facility.
分析記事 • Nov 03Shareholders May Be A Bit More Conservative With Cann Group Limited's (ASX:CAN) CEO Compensation For NowThe underwhelming share price performance of Cann Group Limited ( ASX:CAN ) in the past three years would have...
Executive Departure • Sep 07Chief Financial Officer Greg Bullock has left the companyDuring their tenure, earnings grew by 46% annually compared to the industry average of 17%. On the 1st of September, Greg Bullock left the company after 1.3 in the role. We don't have any record of a personal shareholding under Greg's name. Greg is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.42 years, which is considered inexperienced in the Simply Wall St Risk Model.
Reported Earnings • Aug 24Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)Full year 2021 results: Net loss: AU$25.1m (loss widened 48% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.
お知らせ • May 28Cann Group Limited Revises Revenue Guidance for the Year 2021Cann Group Limited revised revenue guidance for the year 2021. With revenue of $3.2 million so far this financial year (up to the end of April), the company is now forecasting total revenue for the year 2021 of between $4 million and $5 million compared to the previous revised guidance announced 15 February 2021 of between $8 million and $10 million. The revenue guidance adjustment reflects an update to the expected timing of revenue only, with the balance of the 2021 original forecast revenue now expected to be received in 2022.
お知らせ • Mar 11Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million on February 14, 2021. As per the transaction, Cann Group will issue 4.3 million new Cann shares to the value of CAD 2.5 million at completion to Harvest One and and conditional deferred consideration of up to CAD 1.5 million based on achieving agreed operational and financial results and to be paid in new Cann shares or cash at the election of Cann. The number of new Cann shares to be issued to Harvest One at completion will be based on the value of the AUD equivalent of CAD 2.5 million at Completion at an issue price per share to be based on the VWAP of Cann’s shares during the 5 full trading days on the ASX ending on the ASX trading day immediately prior to the date on which completion occurs. In addition to customary terms for a transaction of this nature, the acquisition terms include the satisfaction of certain conditions precedent, including obtaining all necessary regulatory and third-party approvals and consents. The transaction is expected to be completed in March 2021, with the final element of the conditional deferred consideration expected to be paid by September 2021. Moelis Australia acted as financial advisor and William Ross Lawyers & Advisers acted as legal advisor to Cann Group. Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT) on March 10, 2021.
お知らせ • Mar 09Cann Group Limited, Olivia Newton-John Cancer Research Institute and Austin Health Partnered in A Clinical Tria to Assess Medicinal Cannabis for Symptom Management in People with Advanced CancerCann Group Limited and the Olivia Newton-John Cancer Research Institute (ONJCRI), as the La Trobe School of Cancer Medicine, and Austin Health, announced that they have partnered in a clinical trial to assess medicinal cannabis for symptom management in people with advanced cancer. The Phase I trial commenced in late September 2020 and trial outcomes are currently being reviewed, with patients having tolerated the treatment well to date. Phase I is focused on the titration and safety of administering this new formulation of medicinal cannabis in a controlled manner. Should the Phase I study demonstrate safety and tolerability of the drug, Phase II (a double blind, randomised, placebo-controlled trial) will see the enrolment of 108 participants with advanced cancers, subject to meeting trial specific eligibility criteria. The Phase II study will evaluate the efficacy of the drug by assessing global Quality of Life in these participants, as well as other domains including pain, anorexia, nausea, anxiety and sleep. Participants can only be referred to the study by their treating physician.
お知らせ • Mar 03+ 1 more updateCann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT) on February 16, 2021. The aggregate 0.004 million shares will be issued by Cann Group Limited (ASX:CAN) for the transactions.
Reported Earnings • Feb 24First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)First half 2021 results: Net loss: AU$9.40m (loss widened 12% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year and the company’s share price has also fallen by 41% per year.
分析記事 • Feb 23Here's Why We're Not Too Worried About Cann Group's (ASX:CAN) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • Feb 16+ 1 more updateCann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million on February 15, 2021. As per the transaction, Cann Group will issue new Cann shares to the value of CAD 2.5 million at completion to Harvest One and and conditional deferred consideration of up to CAD 1.5 million based on achieving agreed operational and financial results and to be paid in new Cann shares or cash at the election of Cann. The number of new Cann shares to be issued to Harvest One at completion will be based on the value of the AUD equivalent of CAD 2.5 million at Completion at an issue price per share to be based on the VWAP of Cann’s shares during the 5 full trading days on the ASX ending on the ASX trading day immediately prior to the date on which completion occurs. In addition to customary terms for a transaction of this nature, the acquisition terms include the satisfaction of certain conditions precedent, including obtaining all necessary regulatory and third-party approvals and consents. The transaction is expected to be completed in March 2021, with the final element of the conditional deferred consideration expected to be paid by September 2021. Moelis Australia acted as financial advisor and William Ross Lawyers & Advisers acted as legal advisor to Cann Group.
Is New 90 Day High Low • Feb 09New 90-day high: AU$0.78The company is up 144% from its price of AU$0.32 on 11 November 2020. The Australian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 29% over the same period.
Price Target Changed • Jan 08Price target lowered to AU$1.12Down from AU$1.87, the current price target is provided by 1 analyst. The new target price is 76% above the current share price of AU$0.64. As of last close, the stock is down 33% over the past year.
お知らせ • Jan 06Cann Group Limited Receives Initial 19,000 Unit Order for EuropeCann Group Limited announced that it has committed to a minority investment in iuvo Therapeutics Limited and has received an initial order to ship 19,000 units of 30ml extract. Cann Group has made a strategic CAD 1 million cornerstone commitment in a CAD5 million capital raising that is currently being completed by iuvo, resulting in Cann Group holding approximately 2% of iuvo's issued ordinary shares. Funds raised will be used by iuvo to expand sales and marketing capabilities and assist with construction of a new manufacturing and formulation facility in Malta. Following the investment, Cann Group will be granted exclusive external rights to supply iuvo Therapeutics GmbH, iuvo's wholly-owned subsidiary, (`iuvo Germany'), with medicinal cannabis extracts until 31 December 2021, with those rights then converting to preferred non-exclusive status. iuvo has placed an initial 19,000 unit order for Cann product which is expected to be shipped to Germany within the next month, subject to relevant regulatory clearances. Being fully compliant with the latest German monograph addition "Cannabis Extractum Normatum", it will be one of the first full-spectrum extracts available in the market.
分析記事 • Nov 25What Type Of Returns Would Cann Group's(ASX:CAN) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?Cann Group Limited (ASX:CAN) shareholders will doubtless be very grateful to see the share price up 77% in the last...
分析記事 • Nov 25One Forecaster Is Now More Bearish On Cann Group Limited (ASX:CAN) Than They Used To BeMarket forces rained on the parade of Cann Group Limited (ASX:CAN) shareholders today, when the covering analyst...
Major Estimate Revision • Nov 25Analysts update estimatesThe 2021 consensus revenue estimate was lowered from AU$16.0m to AU$14.0m. Earning per share (EPS) estimate was unchanged from the last update at -AU$0.04. The Pharmaceuticals industry in Australia is expected to see an average net income growth of 21% next year. The consensus price target was lowered from AU$1.87 to AU$1.86. Share price is up 77% to AU$0.55 over the past week.
Is New 90 Day High Low • Nov 24New 90-day high: AU$0.51The company is up 22% from its price of AU$0.41 on 26 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Recent Insider Transactions • Oct 20Deputy Chairman recently bought AU$55k worth of stockOn the 13th of October, Philip Robert Jacobsen bought around 144k shares on-market at roughly AU$0.38 per share. In the last 3 months, they made an even bigger purchase worth AU$79k. Philip Robert has been a buyer over the last 12 months, purchasing a net total of AU$156k worth in shares.
お知らせ • Oct 13An unknown buyers acquired 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB).An unknown buyers acquired 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB) on October 9, 2020. Aurora has indicated to Cann Group that its decision to exit a strategic holding in Cann Group. The transaction will not have any impact on Cann Group’s business plans. An unknown buyers completed the acquisition of 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB) on October 9, 2020
Is New 90 Day High Low • Oct 12New 90-day low: AU$0.38The company is down 54% from its price of AU$0.82 on 14 July 2020. The Australian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period.
お知らせ • Sep 21Cann Group Limited(ASX:CAN) dropped from S&P Global BMI IndexCann Group Limited(ASX:CAN) dropped from S&P Global BMI Index
お知らせ • Aug 19Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 25.9 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 25.9 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 64,750,000 Price\Range: AUD 0.4 Discount Per Security: AUD 0.012
お知らせ • Jul 24Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 14.3 million.Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 14.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 35,750,000 Price\Range: AUD 0.4 Discount Per Security: AUD 0.008 Transaction Features: Subsequent Direct Listing
